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Background: Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained
release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some
parameters of renal filtration function, containing in slope of 1/serum creatinine (1/SCr) vs. time in a phase II clinical trial.
Methods/design: We describe the design of the phase IIb/III trial of TRK-100STP, CASSIOPEIR (CRF Asian Study with Oral
PGI2 derivative for Evaluating Improvement of Renal function) conducted in approximately 160 centers in China, Hong
Kong, Japan, Malaysia, Republic of Korea, Taiwan, and Thailand. A total of 750 patients (n = 250 per group) with primary
glomerular disease or nephrosclerosis were planned to be enrolled. Patients were randomized into one of three treatment
groups in a double-bind, placebo-controlled manner: TRK-100STP 60 μg b.i.d.; TRK-100STP 120 μg b.i.d.; or placebo. The
treatment period is planned to last 2 to 4 years. The primary efficacy endpoint is the renal composite endpoint
including doubling of SCr and ESRD (dialysis induction, renal transplantation, or increase in SCr to ≥6.0 mg/dL).
Discussion: This trial targeting CKD patients is designed to (a) demonstrate the superiority of TRK-100STP over
placebo using renal composite endpoints, (b) determine the recommended clinical dose, and (c) assess the
safety of TRK-100STP in this population and setting.
Trial registration: ClinicalTrials.gov Identifier: NCT01090037.
Keywords: Prostacyclin analogue, PGI2, Beraprost sodium, Chronic kidney disease, Primary glomerular disease,
Nephrosclerosis, Serum creatinine, Renal composite endpoint, CASSIOPEIR, TRK-100STPBackground
The number of patients with end-stage renal disease
(ESRD) requiring dialysis or renal transplantation has
increased globally in recent years. Among the primary
diseases that lead to ESRD are the primary and secondary
glomerular diseases such as diabetic nephropathy and
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article, unless otherwise stated.Primary glomerular diseases and nephrosclerosis still
comprise a significant proportion of chronic kidney
disease (CKD) patients. Primary glomerular diseases are es-
pecially important causes for the need for dialysis in Asian
countries. They are currently the most frequent causes in
China [1] and the second in most other Asian countries
[2-4]. Nephrosclerosis is the third frequent cause in most
Asian countries and has been increasing [1-5].
The primary care of CKD treatment is to delay renal
function deterioration. Current treatments include dietarytral Ltd. This is an Open Access article distributed under the terms of the
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converting enzyme inhibitors (ACEIs) and angiotensin-II
receptor blockers (ARBs), which are often administered to
both diabetic nephropathy and non-diabetic CKD patients,
have been established as the recommended treatment
agents for non-diabetic nephropathy patients [6], although
either ACEIs or ARBs are insufficient for the prevention of
progressive renal disease. Therefore, an additional treat-
ment that is able to significantly delay the progression of
CKD is highly coveted.
To meet this unmet medical need, clinical trials have
been conducted attempting to delay CKD progression
with combination therapies using renin-angiotensin
system (RAS) inhibitors. Unfortunately, these trials failed
to show an improvement in efficacy with composite
renal endpoints while adverse events increase in some
of them. Clinical benefits of combination treatments
with multiple RAS inhibitors are therefore unproven,
at least for diabetic nephropathy [7-10].
Furthermore, a recent trial of Nrf2-activating bardoxo-
lone methyl in diabetic nephropathy patients (BEACON)
was prematurely terminated due to safety concerns [11].
A trial of an orally administered activated carbon prepa-
ration (AST120: Kremezin®), which is currently used in
clinical practice for chronic renal failure in Japan,
Republic of Korea and Taiwan, also failed to meet the
efficacy endpoints in composite renal endpoint in the
large EPPIC randomized controlled trials [12]. The
development of a novel CKD treatment strategy is there-
fore increasingly needed.
Beraprost sodium (BPS) is a stable orally-active prosta-
cyclin (PGI2) analogue discovered by Toray Industries,
Inc. to overcome instability of prostacyclin in vivo [13].
BPS has a novel mechanism for suppressing the prog-
ression of CKD. This treatment also targets renal
hypoxia, reflecting a growing body of evidence impli-
cating this as a valid therapeutic approach [14]. BPS has
been found to be effective in various animal models of
renal disorders [15-19]. In addition, BPS immediate-
release tablets prevented the decrease in renal blood
flow and function in patients with chronic renal failure
[20,21].
Using sustained release tablets of BPS (TRK-100STP),
a randomized double-blind placebo-controlled compara-
tive phase II trial aiming to determine the optimal clin-
ical dose was conducted from 2005 to 2008 in Japanese
patients with primary glomerular disease or nephro-
sclerosis as the primary disease [22]. In this trial, serum
creatinine (SCr) values were 1.5 to 4.5 for male and 1.3
to 4.0 for female at the initiation of treatment. Randomized
patients received oral TRK-100STP 120 μg/day (60 μg b.i.d.),
240 μg/day (120 μg b.i.d.) or placebo for 28 weeks after the
22-week run-in period. The primary endpoint was the differ-
ence in slope of 1/SCr vs. time between the run-in periodand the treatment period. No statistical difference in
the primary endpoint was found between the high-dose
(240 μg) group and the placebo group and so a clinical
dose recommendation was not determined. Both treat-
ment groups showed better outcomes than the placebo
group, with the low-dose (120 μg/day) group showing the
highest efficacy. Both active dose groups showed similar
effectiveness for additional efficacy endpoints including
creatinine clearance, SCr ratio and serum cystatin C,
compared to those of the placebo group.
A subgroup analysis was also conducted in the same
study among patients with SCr 2.0 mg/dL or higher,
whose renal function deterioration was considered ir-
reversible [23]. Deteriorations in all the representative
renal filtration functions (i.e. difference in the slope of
the 1/SCr vs. time between the run-in period and the
treatment period, SCr ratio, serum cystatin C and eGFR)
were suppressed in the treatment groups and significant
suppressions have been observed in some of these
parameters. On the other hand, no clinically relevant
safety issues were observed.
Based on these results, it was judged that a hypo-
thesis could be set up to be verified in the phase IIb/III
trial. The clinically recommended dose is to be re-
evaluated using the same doses as ones in the phase II
trial.
This paper details the design and methodology of a phase
IIb/III trial (CASSIOPEIR: CRF Asian Study with Oral
PGI2 derivative for Evaluating Improvement of Renal func-
tion) conceived on the basis of the evidence and findings
mentioned above in order to investigate whether TRK-
100STP is superior to placebo in treating patients with pri-
mary glomerular disease or nephrosclerosis. Evaluating
composite renal endpoints, the trial aims also to determine
a recommended therapeutic dose of TRK-100STP.
Methods/design
Aim of trial
This is a multicenter, randomized, double-blind, placebo-
controlled, parallel-group comparative trial targeting CKD
patients designed to: (a) demonstrate the superiority of
TRK-100STP over placebo using renal composite end-
points, including the extension of the time to the start of
dialysis treatment; (b) determine the recommended
clinical dose by comparing the low-dose (120 μg/day),
high-dose (240 μg/day), and placebo groups; and (c) assess
the safety of TRK-100STP in this population and setting.
Study design
The trial is being conducted in approximately 160 sites,
including centers in China, Hong Kong, Japan, Malaysia,
Republic of Korea, Taiwan and Thailand. The protocol
has been approved by the Ethics Review Committee/
Institutional Review Board affiliated with each center.
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Clinical Practice, and Declaration of Helsinki. All pa-
tients provided written informed consent. The trial has
been registered on ClinicalTrials.gov, NCT01090037.
A total of 750 patients (n = 250 per group) with pri-
mary glomerular disease or nephrosclerosis are planned
to be randomized. The rationale for setting the sample
size at 250 subjects per group is based on “data handling
procedure #2: 3-month lag censoring analysis” as
follows. In the event of doubling of SCr or increase in
SCr to ≥6.0 mg/dL, the 2.5-year event rate estimated
from subjects with SCr ≥2.0 mg/dL that were enrolled in
the last phase II trial was 48% for the placebo group and
33% for 240 μg group. Therefore, assuming a 2-year-
enrollment period, a 2-year follow-up period, and a 35%
dropout rate at 2.5 years for each group, the number of
subjects required per group is estimated at 237 (with two-
sided 5% significance level and 90% statistical power). For
all subjects, placebo was orally administered for 2 to
8 weeks, twice a day, during the run-in period, when
subjects were blinded although investigators recognized
that subjects received placebo (Figure 1). Prohibited and
restricted concomitant medications are detailed in Table 1.
Subjects who met the inclusion and exclusion criteria
(summarized in Table S2; see Additional file 1) after
2-to-8-week run-in period were randomized into one
of three treatment groups for the 2-to-4-year treat-
ment period in a double-bind manner: TRK-100STP
120 μg; TRK-100STP 240 μg; or placebo. Subjects
randomized in the 240 μg dose group started with a
daily dose of 120 μg for 2 weeks and was then
increased to 240 μg/day. While the treatment period
was planned to last for 2 to 4 years, this may be
extended if the incidence of renal composite endpoint
is smaller than expected.Figure 1 Schematic diagram of the CRF Asian Study with Oral PGI2 de
(CASSIOPEIR) study design.Study endpoints
The primary efficacy endpoint for the trial is the renal
composite endpoint (time to first occurrence of one of
the following events): 1) Doubling of SCr; defined as at
least a two-fold increase in SCr during the treatment
period over the baseline value during the run-in period
(mean value of the last two measurement results during
the run-in period); and 2) ESRD (occurrence of any of
the following: introduction of dialysis, renal transplant-
ation, or increase in SCr to ≥6.0 mg/dL). With regards to
the doubling of SCr, and the increase in SCr to ≥6.0 mg/dL,
a re-confirmation will be performed with blood sample col-
lection and measurement four or more weeks after the ini-
tial date on which these endpoints were confirmed, and
once reconfirmed, the initial date will be judged as the date
on which these renal composite endpoints are reached. The
clinical trial and administration of the study drug will be
continued for the subject even after the confirmation that
SCr has doubled or increased to ≥6.0 mg/dL until introduc-
tion of dialysis or renal transplantation is deemed necessary.
If the administration of the study drug is prematurely dis-
continued during the treatment period, the clinical study
will be continued as an efficacy follow-up until introduction
of dialysis or renal transplantation is judged to be needed.
Secondary endpoints are as follows: 1) Renal composite
endpoint or death (from any causes); 2) doubling of SCr;
3) ESRD; 4) introduction of dialysis; 5) renal transplant-
ation; 6) increase in SCr to ≥6.0 mg/dL; 7) slope of 1/SCr
vs. time; and 8) eGFR. In addition, the safety endpoints
include adverse events, laboratory tests, vital signs and
body weight, and 12-lead electrocardiogram (ECG). Also
to be evaluated are miscellaneous efficacy endpoints such
as “cardiovascular events or renal composite endpoints”.
All SCr values used for analysis of the endpoints are
measured at the central clinical laboratory.rivative for Evaluating Improvement of Renal function
Table 1 Prohibited and restricted concomitant medications
Prohibited Concomitant Medications The following medications are prohibited for use during the study period.
(1) Prostaglandin drugs except for ophthalmic solutions and ointments.
(2) Fluorinated pyrimidine antifungal agents.
Restricted Concomitant Medications (1) For ACEIs and ARBs, changing the dose or introducing the medication is not permitted from the
obtaining of informed consent to the end of the study drug administration. Antihypertensive drugs
other than ACEIs or ARBs are permitted to be used.
(2) From obtaining of informed consent to the end of the study drug administration, changing the
dose or introducing the medication is not permitted for pentoxifylline, dilazep hydrochloride, or
dipyridamole.
(3) From obtaining of informed consent to the end of the study drug administration, NSAIDs are
not permitted to be taken for more than four consecutive weeks; and during the week prior to a
visit, NSAIDs are not permitted to be taken.
Nakamoto et al. BMC Nephrology 2014, 15:153 Page 4 of 8
http://www.biomedcentral.com/1471-2369/15/153Analysis set
The full analysis set (FAS) will consist of subjects taking
at least one dose of study drug for the treatment period.
However, subjects meeting the following descriptions are
excluded from the FAS:
1. Subjects providing no data after administration of
the study drug for the treatment period;
2. Subjects found not to fulfill the inclusion criterion
(2) or (3);
3. Subjects found to meet the exclusion criterion (1),
(2), or (6).
Subjects who satisfy all of the following criteria out of
FAS constitute the per protocol set (PPS), and are:
1. Subjects meeting the inclusion criteria;
2. Subjects not meeting the exclusion criteria;
3. Subjects providing three or more SCr measurement
data points obtained at and after Week 4 of the
treatment period (including at least one data point
taken at Day 70 of the treatment period or later);
4. Subjects whose drug compliance rate is two-thirds
or higher during the administration period of the
study drug for the treatment period.
The safety analysis set (SAF) will include subjects
taking at least one dose of the study drug for the treat-
ment period.
The pharmacokinetics analysis set (PKAS) is defined
by subjects fulfilling all of the following criteria:
1. Subjects taking at least one dose of the study drug
for the treatment period;
2. Subjects providing at least one data point (sample)
for plasma BPS concentration determination for
which information on the date and time of blood
collection and medication before the collection is
available.Handling of data
For efficacy assessment, the following three types of data
handling processes have been established:
(1)Data Handling Procedure #1
All data will be adopted for analysis that is obtained
after the start of the administration of the study
drug for the treatment period (Intension-To-Treat
(ITT) analysis).
(2)Data Handling Procedure #2
For subjects who discontinue the administration of
the study drug for the treatment period, their data
obtained after 3 months following the
discontinuation will not be used, and data collection
for them is censored at 3 months from the
discontinuation or at completion of the study,
whichever comes first (3-month lag censoring
analysis).
(3)Data Handling Procedure #3
Subjects that take a prohibited concomitant
medication will be censored at the time of the
medication. Subjects will be censored at any time
when they stop taking the study drug for the
treatment period, for whatever reason.
Analysis of efficacy
The primary population for efficacy analysis will be the
FAS, and the data will be processed according to the
Data Handling Procedure #1. Similar analyses will be
conducted according to the Data Handling Procedure #2
in terms of FAS and according to the Data Handling
Procedure #3 in terms of PPS. Statistical testing will use
two-sided 5% significance level and calculate two-sided
95% confidence interval, unless otherwise specified.
Analysis of safety
Vital signs, adverse events, laboratory tests, body weight,
12-lead electrocardiogram (ECG) and pregnancy test will
be performed for the purpose of safety evaluation.
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Analysis of pharmacokinetics will be conducted using
PKAS. During the treatment period the participants will
make five visits prior to the study drug administration in
the morning for a blood test. They will make another six
visits after taking the morning dose to have blood sam-
ples collected. The time from the drug administration
will be recorded, and the serum BPS level is to be deter-
mined. The population pharmacokinetics analysis will be
conducted in addition to the pharmacokinetics analysis.
Statistical evaluation
For the analysis of efficacy, the renal composite endpoint
will be treated as an event and this evaluation will be
conducted in the following steps. Step 1: Based on Cox’s
proportional hazard model with the region as a covari-
ate, contrast test will be performed on the comparison
coefficient (1, -1/2, -1/2) for the placebo group, 120 μg
group, and 240 μg group at two-sided 5% significance
level. Step 2: If a statistical significance was observed in
Step 1, pair-wise comparison between the placebo and
the 120 μg groups and between the placebo group and
the 240 μg group will be performed at a two-sided 5%
significance level using Cox’s proportional hazard model
with the region as a covariate.
Endpoint judgment committee
Prior to the start of the study, an Endpoint Judgment
Committee (EJC) was established. The committee is com-
prised of three committee members who are not involved
directly in the study. The committee will examine, par-
ticularly, the validity of dialysis introduction, renal trans-
plantation and cardiovascular events, among the efficacy
endpoints in each institution.
Data and safety monitoring board
Prior to the start of the study, the Data and Safety Moni-
toring Board (DSMB) was established. The committee is
comprised of three committee members who are not
involved directly in the study. The safety evaluation
committee assesses safety data including serious adverse
events.
Results
The first patient was enrolled in this trial in June 8,
2010. A total of 1105 subjects were enrolled in run-in
period. From July 8, 2010 through April 26, 2012 a total
of 892 subjects underwent randomization (200 in China,
13 in Hong Kong, 339 in Japan, 46 in Malaysia, 135 in
Republic of Korea, 108 in Taiwan and 51 in Thailand).
The EJC and DSMB have been conducted 2 and 3
times to date, respectively and have concluded that there
is no concern regarding the continuation of this trial.Discussion
This is a multicenter, randomized, double-blind, placebo-
controlled, parallel-group comparative trial targeting CKD
patients designed to, (a) demonstrate the superiority of
TRK-100STP over placebo using renal composite end-
points, (b) determine the recommended clinical dose,
which was not established following the respective phase
II trial, and (c) assess the safety of TRK-100STP in this
population and setting.
Prostacyclin, which was discovered in 1976, was ex-
pected to be a key advance for novel pharmacotherapy
for various cardiovascular diseases [24]. However, pros-
tacyclin proved to be an unstable chemical substance
having a short elimination half-life in blood plasma. The
clinical use of prostacyclin was consequently limited to
serious cases of pulmonary arterial hypertension (PAH)
for which 24-hour continuous infusion is indicated [25].
BPS is a stable orally-active prostacyclin analogue and
its immediate-release tablet obtained manufacturing ap-
proval for the treatment of chronic arterial occlusive dis-
eases from the Japanese regulatory agency in January
1992 (brand names: Dornar® and Procylin®). An add-
itional indication for primary pulmonary hypertension
was approved in September 1999. Besides Japan, BPS
immediate-release tablets were launched in other Asian
markets including China, Indonesia, Republic of Korea,
Thailand and The Philippines, between 1997 and 2006.
TRK-100STP, a hydrogel-forming matrix preparation,
provides a sustained-release preparation of BPS [26]. In
October 2007, TRK-100STP was given marketing approval
in Japan for the treatment of PAH with a maximum daily
dose of 360 μg (180 μg b.i.d.) (Brand names: Careload®
and Berasus®). The maximum daily clinical dose of TRK-
100STP has doubled those of the immediate-release tablet
for the indication of pulmonary hypertension in Japan.
BPS has the same pharmacological actions as those of
natural prostacyclin, including anti-platelet and vasodi-
lating effects [27], as well as being able to protect vascular
endothelial cells [28] and inhibit inflammatory cytokines
production including MCP-1 [17].
The importance of tubulointerstitial hypoxia has
recently been highlighted as the final common pathway
of CKD [29], a notion supported by an increasing body
of evidence from animal models [14,30,31] and clinical
study [32]. Renal blood flow is reduced when renal
glomeruli are damaged by pathological factors such as
inflammation and hypertension. Lack of oxygen, particu-
larly in the tubulointerstitium of the outer-medullary re-
gion which is susceptible to hypoxia, triggers further
damage to renal glomeruli which causes renal function
to progressively decline [33]. It has been demonstrated,
in the glomerular nephritis rat model, that the beneficial
effects of BPS are attributed, at least in part, to the
amelioration of tubulointerstitial hypoxia [19].
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diminishes blood pressure or brings about increased heart
rate (HR) as compensation in several animal species [27].
However, neither increased HR nor lower blood pressure
is observed at the clinical dose up to 180 μg b.i.d. in
patients with PAH [34]. Additionally, the phase II trial of
CKD patients demonstrated that TRK-100STP up to
120 μg b.i.d. does not affect either blood pressure or
urinary protein. Thus the effect of BPS to suppress the
reduction of renal function is not related to blood pressure
lowering or to reducing urinary protein levels. This
suggests that the mechanism of beneficial effect of BPS for
renal function is different from that of ACEIs/ARBs.
Other features of this trial are as follows:
1) Treatment with TRK-100STP is employed, in principle,
as an add-on to existing treatments. No limitation was
set against concomitant ACEIs/ARBs use, although dose
alternation and newly initiated prescription is restricted.
Meanwhile recent evidence from large-scale clinical
studies indicates that combination therapy with RAS
inhibitors is not effective and also increases certain
safety concerns in some of them. The add-on approach
was therefore chosen in this trial, based on the
observation that a new approach is required beyond
RAS inhibitor-based combination therapy.
2) This trial utilizes carefully defined eligibility criteria
that allows for sufficient numbers of events while
excluding slow-progressing patients. This is important
because the pace of renal function deterioration varies
widely among patients, especially among non-diabetic
CKD patients where disease progression is sometimes
very slow. Enrollment is limited to patients with SCr
of 2 mg/dL or higher where an irreversible decrease in
renal function is reported [23]. Clinical benefits were
more clearly apparent in such patients in the previous
phase II trial [22]. Participants must also have
experienced progression in renal function deterioration,
assessed by the slope of 1/SCr vs. time, within one year
before the start of the study. These aspects of
recruitment may subsequently help us define the
target population likely to benefit most from intervention.
3) The necessity of introduction of dialyses or kidney
transplants were determined by the principal
investigator based on medical need assessment.
All endpoints including the dates of introduction
of dialyses or kidney transplants, as well as
cardiovascular event occurrence, were validated by
an EJC whose members are third-party physicians.
4) Patients with diabetes at pre-enrollment were
excluded. The findings of several animal model
studies have indicated that BPS may be effective
against diabetic nephropathy [35-37]. Researchers
have also reported that BPS was effective in patientswith microalbuminuria [38]. However, there are
several methodological difficulties in covering both
diabetic and non-diabetic CKD in a single study
protocol. In addition, considering there is a great
unmet need for non-diabetic nephropathy treatment
in Asia, we decided to prioritize and focus on non-
diabetic CKD, wherein renal disorders are not
modified by diabetes. As it is difficult in practice to
definitively distinguish between patients with diabetic
nephropathy and non-diabetic CKD patients with
diabetes, all patients with diabetes at pre-enrollment
are excluded.
In the original trial design, handling of primary data was
stipulated as “3-month lag censoring analysis”. However,
Japanese regulatory authority, Pharmaceuticals and Medical
Devices Agency (PMDA), advised that ITT analysis should
be primary analysis. The priority order of data handling was
therefore amended based on the PMDA’s advice. Mean-
while, the sample size estimation and rationale for setting
the sample size in “study design”, which was designed based
on 3-month lag censoring analysis, was not amended.
Conclusion
This trial evaluates the efficacy and safety of TRK-100STP
in the treatment of patients with primary glomerular
disease or nephrosclerosis using renal composite end-
points, and also aims to establish a recommended dose of
TRK-100STP to optimize clinical outcomes.
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